Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Inflammation is the major etiologic factor in the development of pseudophakic cystoid macular edema (CME). Several soluble mediators of inflammation such as tumor necrosis factor alpha (TNF-α) have been implicated in the pathogenesis of ocular inflammation. The purpose of this study is to report the short-term visual and anatomic outcomes following intravitreal injections of infliximab in eyes with refractory CME secondary to cataract surgery. An interventional, retrospective study of 7 eyes with refractory CME that were injected with 1 mg of infliximab. The main outcome measures were best-corrected visual acuity (BCVA) and central macular thickness (CMT) at 6-month follow-up. At the 6 month follow-up, BCVA improved from 1.14 ± 0.59 logMAR at baseline to 0.51 ± 0.35 logMAR (p = 0.0156). CMT also improved from 584 ± 159 μm at baseline to 327 ± 127 μm at 6 months (p = 0.0111). No systemic adverse events were reported in these patients. There was a single episode of uveitis that responded to topical steroids. Inhibition of TNF-α may be beneficial in the treatment of refractory pseudophakic CME.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Flach AJ (1998) The incidence, pathogenesis and treatment of cystoid macular edema following cataract surgery. Trans Am Ophthalmol Soc 96:557–634

    PubMed  CAS  Google Scholar 

  2. Gallego-Pinazo R, Arevalo JF, Udaondo P, Garcia-Delpech S, Dolz-Marco R, Diaz-Llopis M (2011) Prophylaxis of pseudophakic cystoid macular edema with intraoperative pegaptanib. J Ocul Pharmacol Ther 28:65–68

    Article  PubMed  Google Scholar 

  3. Levin DS, Lim JI (2002) Update on pseudophakic cystoid macular edema treatment options. Ophthalmol Clin North Am 15:467–472

    Article  PubMed  Google Scholar 

  4. Stark WJ Jr, Maumenee AE, Fagadau W, Datiles M, Baker CC, Worthen D, Klein P, Auer C (1984) Cystoid macular edema in pseudophakia. Surv Ophthalmol 28(Suppl):442–451

    Article  PubMed  Google Scholar 

  5. Miyake K, Ibaraki N (2002) Prostaglandins and cystoid macular edema. Surv Ophthalmol 47(Suppl 1):S203–S218

    Article  PubMed  Google Scholar 

  6. Rabinovich CE (2007) Use of tumor necrosis factor inhibitors in uveitis. Curr Opin Rheumatol 19:482–486

    Article  PubMed  CAS  Google Scholar 

  7. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM, Gomez Vidal MA, Collantes Estevez E, Ramirez Chamond R, Omar M (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33:251–255

    Article  PubMed  CAS  Google Scholar 

  8. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE (2004) Macular edema. Surv Ophthalmol 49:470–490

    PubMed  Google Scholar 

  9. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA (2003) Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 29:27–33

    Article  PubMed  Google Scholar 

  10. Rho DS (2003) Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 29:2378–2384

    Article  PubMed  Google Scholar 

  11. Steinert RF, Wasson PJ (1989) Neodymium:YAG laser anterior vitreolysis for Irvine-Gass cystoid macular edema. J Cataract Refract Surg 15:304–307

    PubMed  CAS  Google Scholar 

  12. Harbour JW, Smiddy WE, Rubsamen PE, Murray TG, Davis JL, Flynn HW Jr (1995) Pars plana vitrectomy for chronic pseudophakic cystoid macular edema. Am J Ophthalmol 120:302–307

    PubMed  CAS  Google Scholar 

  13. Arevalo JF, Garcia-Amaris RA, Roca JA, Sanchez JG, Wu L, Berrocal MH, Maia M (2007) Primary intravitreal bevacizumab for the management of pseudophakic cystoid macular edema: pilot study of the Pan-American Collaborative Retina Study Group. J Cataract Refract Surg 33:2098–2105

    Article  PubMed  Google Scholar 

  14. Arevalo JF, Maia M, Garcia-Amaris RA, Roca JA, Sanchez JG, Berrocal MH, Wu L (2009) Intravitreal bevacizumab for refractory pseudophakic cystoid macular edema: the Pan-American Collaborative Retina Study Group results. Ophthalmology 116:1481–1487, 1487 e1481

    Google Scholar 

  15. Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP (2004) Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 138:648–650

    Article  PubMed  CAS  Google Scholar 

  16. Suhler EB, Smith JR, Giles TR, Lauer AK, Wertheim MS, Kurz DE, Kurz PA, Lim L, Mackensen F, Pickard TD, Rosenbaum JT (2009) Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 127:819–822

    Article  PubMed  CAS  Google Scholar 

  17. Suhler EB, Smith JR, Wertheim MS, Lauer AK, Kurz DE, Pickard TD, Rosenbaum JT (2005) A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol 123:903–912

    Article  PubMed  CAS  Google Scholar 

  18. Kruglov AA, Kuchmiy A, Grivennikov SI, Tumanov AV, Kuprash DV, Nedospasov SA (2008) Physiological functions of tumor necrosis factor and the consequences of its pathologic overexpression or blockade: mouse models. Cytokine Growth Factor Rev 19:231–244

    Article  PubMed  CAS  Google Scholar 

  19. Giansanti F, Ramazzotti M, Vannozzi L, Rapizzi E, Fiore T, Iaccheri B, Degl’ Innocenti D, Moncini D, Menchini U (2008) A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 49:1151–1156

    Article  PubMed  Google Scholar 

  20. Theodossiadis PG, Liarakos VS, Sfikakis PP, Charonis A, Agrogiannis G, Kavantzas N, Vergados IA (2009) Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol 247:273–281

    Article  PubMed  CAS  Google Scholar 

  21. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP (2009) Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. Am J Ophthalmol 147:825–830, 830 e821

    Google Scholar 

  22. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N (2010) Adverse events after intravitreal infliximab (Remicade). Retina 30:71–80

    Article  PubMed  Google Scholar 

  23. Kent D, Vinores SA, Campochiaro PA (2000) Macular oedema: the role of soluble mediators. Br J Ophthalmol 84:542–545

    Article  PubMed  CAS  Google Scholar 

  24. Farvardin M, Afarid M, Mehryar M, Hosseini H (2010) Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina 30:1530–1535

    Article  PubMed  Google Scholar 

  25. Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J, Pujol O (2010) Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina 30:1601–1608

    Article  PubMed  Google Scholar 

  26. Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF (2011) Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 31:298–303

    Article  PubMed  CAS  Google Scholar 

  27. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P (2010) Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 117:1612–1616

    Article  PubMed  Google Scholar 

  28. Tsilimbaris M, Diakonis VF, Naoumidi I, Charisis S, Kritikos I, Chatzithanasis G, Papadaki T, Plainis S (2009) Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol 247:1119–1125

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Supported in part by the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela.

Author information

Authors and Affiliations

  1. Instituto de Cirugia Ocular, Apdo 144-1225 Plaza Mayor, San José, Costa Rica

    Lihteh Wu & Erick Hernandez-Bogantes

  2. Retina and Vitreous Service, Clinica Oftalmológica Centro Caracas, Caracas, Venezuela

    J. Fernando Arevalo

  3. Clínica Ricardo Palma, Lima, Peru

    José A. Roca

Authors
  1. Lihteh Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Fernando Arevalo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Erick Hernandez-Bogantes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José A. Roca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lihteh Wu.

Additional information

For a complete listing of participating members of PACORES see Appendix.

Appendix

Appendix

The following investigators belong to the Pan-American Collaborative Retina Study Group (PACORES):

The Pan-American Collaborative Retina Study Group (PACORES): L. Wu (PI), Teodoro Evans, Erick Hernandez-Bogantes, Instituto de Cirugia Ocular, San Jose, Costa Rica; J.F. Arevalo (PI), J.G. Sanchez, Clinica Oftalmologica Centro Caracas and the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela; M. Farah (PI), M. Maia, Universidade Federal de São Paulo, Departamento de Oftalmologia, Instituto da Visão, Sao Paulo, Brazil; V. Morales-Canton (PI), H. Quiroz-Mercado, J. Fromow-Guerra, J.L. Guerrero-Naranjo, J. Dalma-Weiszhausz, Asociación para Evitar la Ceguera en México, Mexico City, Mexico; F.J. Rodriguez (PI), R. Infante, D. Medina, Fundacion Oftalmologica Nacional, Universidad del Rosario, Bogota, Colombia; M.H. Berrocal (PI), V. Cruz-Villegas, University of Puerto Rico, San Juan, Puerto Rico; F. Graue-Wiechers (PI), D. Lozano-Rechy, Fundacion Conde Valenciana, Mexico City, Mexico; J.A. Roca (PI), Clínica Ricardo Palma, Lima, Peru; M. J. Saravia (PI), M. Martinez-Cartier, Hospital Universitario Austral, Buenos Aires, Argentina; M. Avila (PI), Universidade Federal de Goiás, Departamento de Oftalmologia, Goiânia, Brazil; J. Cardillo (PI), Hospital de Olhos de Araraquara, and the Universidade de Sao Paulo, Sao Paulo, Brazil; J. Verdaguer T. (PI), C. Carpentier, J.I. Verdaguer D., L. Filsecker, G. Sepúlveda, Fundacion Oftalmologica Los Andes, Santiago de Chile, Chile; A. Alezzandrini (PI), F. Sanchez, C. Marini, B. Garcia, OFTALMOS, Catedra de Oftalmologia, Universidad de Buenos Aires, Buenos Aires, Argentina.

PI = Principal Investigator.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, L., Fernando Arevalo, J., Hernandez-Bogantes, E. et al. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group. Int Ophthalmol 32, 235–243 (2012). https://doi.org/10.1007/s10792-012-9559-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-012-9559-8

Keywords

Search

Navigation